Abstract Background Piperacillin-tazobactam (TZP) is one of the most common antibiotics administered to hospitalized patients. Its broad activity against gram-negative, gram-positive, and anaerobic pathogens. The Clinical and Laboratory Standards Institute (CLSI) publishes revised TZP breakpoints in 2022. The purpose of this study was to evaluate the impact of changing the TZP breakpoint in a regional teaching hospital in southern Taiwan. Methods We retrospectively evaluated TZP for 1347 Enterobacterales isolates identified by MALDI-TOF (Bruker Daltonik, Bremen, Germany) between September 1, 2022, through December 31, 2022, at Chang Gung Memorial Hospital in Chiayi. Blood antimicrobial susceptibility testing was performed using an NMIC-411 panel on the BD Phoenix™ M50. The antibiotic susceptibility test of Enterobacterales from other sources of infection used the Disk diffusion method (Kirby-Bauer Method). Susceptibilities were assessed based on historic CLSI breakpoints in 2021 as well as the current CLSI breakpoints from the most recent CLSI MIC breakpoints, the 32th edition of document M100, published in 2022. Results We evaluated 1347 Enterobacterales isolates. Most isolates identified were Escherichia coli [n = 768 (57%)] and Klebsiella pneumoniae [n = 286(21.2%)]. The new TZP breakpoints reduced the percentage of strains that were previously judged to be susceptible by CLSI M100-S31 from 80.9%(1090/1347) to 50%(674/1347). The majority of isolates 674(50%) were susceptible; 416 (30.9%) isolates were susceptible-dose dependent and 257 (19.1%) were resistant to piperacillin/tazobactam using the new CLSI breakpoints. The results of the analysis of the source of infection found that the bacteria that had the greatest impact on the respiratory tract decreased from 43.6% to 12.7%, followed by the genitourinary tract infection decreased from 80.4% to 27%, bodily fluid infection decreased from 69.8% to 24.5%, and abscesses,wounds,pus decreased from 72.7% to 28.1%; The most insignificant are blood infection strains, from 83.1% to 81.3%. Conclusion Our results indicate an increase in resistance to Enterobacterales isolates tested. Non- susceptible to piperacillin/tazobactam from 19.1% to 50% using the revised CLSI breakpoints. The decreased susceptibilities make it clear that microbiology laboratories should accept new MIC breakpoints. Although our study has demonstrated decreased susceptibilities, there is no correlation with clinical outcomes. In conclusion, changes in breakpoints had a significant impact on the susceptibility of TZP for Enterobacterales isolates in our study. Understanding and evaluating the impact of the breakpoint changes is of paramount importance. Institutions should ensure that their breakpoints are up to date to allow for the most optimized treatment.
Read full abstract